Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The #pledgemyeyes initiative reached out to over 30 million people across the country and the website registered 3X more pledges compared to the present numbers
The virtual event will be attended by representatives from state & district health administration, corporates, industries, civil society, and NGOs as the country reiterates its commitment towards TB elimination by 2025
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Subscribe To Our Newsletter & Stay Updated
